Feature | December 02, 2013

Study Shows Use of Topera’s 3-D Rotor Mapping System Improves Long-Term Outcomes for AF Patients

One year, single procedure freedom from AF of 80.5 percent achieved in largely persistent AF population

topera 3-d ep lab atrial fibrillation therapies mapping/imaging systems
December 2, 2013 — Topera Inc. shared the results of an independent evaluation of its diagnostic system’s ability to improve atrial fibrillation (AF) outcomes by identifying of the sources that sustain complex cardiac arrhythmias. The results of the study “Ablation of Atrial Fibrillation Rotors and Focal Sources Improves Outcome Over Conventional Ablation Alone in Independent Laboratories: Multicenter Validation of Focal Impulse and Rotor Modulation (FIRM),” were presented at the American Heart Association Scientific Sessions 2013 Conference in Dallas by John Miller, M.D., director of Clinical Cardiac Electrophysiology, Krannert Institute of Cardiology, Indiana University and lead author of the study.
 
“Maintaining one year freedom from AF in more than 80 percent of patients after a single procedure is highly unusual and achieving this result in this largely persistent AF population is frankly remarkable,” said Professor Miller. “These patients have historically responded poorly to therapy and are our most challenging AF patients to treat. Now, guided by Topera’s 3-D mapping system, we have an effective approach to help them. After two years using the mapping system and monitoring these patients for the past year, it's heartening to see our hopes for, and early experiences with, this technology finally result in excellent long-term outcomes."
 
Study design:
  • One hundred forty-nine patients in a comparative study from 11 U.S. centers in 10 states
  • Seventy-eight AF patients from 10 independent centers in the FIRM-guided (active) arm with a ratio of 70.5 percent persistent to 29.5 percent Paroxysmal AF
  • All patients underwent evaluation and follow up for at least one year
  • Patients receiving FIRM-guided care were compared to 71 control arm patients where RhythmView was not used and only standard of care mapping and ablation were employed
  • Single procedure results were reported, as repeat procedures were considered a failure in outcome, even if during the initial three-month post-procedure period
 
Topera did not participate in the data gathering, evaluation or analysis of the data and did not provide sponsorship or support for the study by these investigators.
 
Study results
Independent centers experienced very similar results to those reported in the original CONFIRM trial. Rotors and focal sources that sustain cardiac arrhythmias were identified in 100 percent of patients, and 50 percent of these patients had rotors in the right atrium, an area in the heart not historically believed to contain sources sustaining atrial fibrillation. 80.5 percent of patients experienced freedom from AF over one year following a single procedure.
 
“This is the third major clinical study that has evaluated the Topera 3D mapping system’s ability to help electrophysiologists identify the sources sustaining complex arrhythmias,” said Ruchir Sehra, M.D. and chief medical officer, Topera. “These studies have consistently demonstrated long-term freedom from AF in excess of 80 percent when our diagnostic mapping system was used. This is now the second study to demonstrate that these remarkable results can also be achieved by physicians in laboratories, independent of the company or the founding inventor.”
 
About the RhythmView Workstation and FIRMap catheter
Using electrograms captured with the FIRMap panoramic contact-mapping basket catheter, the RhythmView Workstation then provides electrophysiologists with a dynamic representation of the electrical activity of the heart. Clinicians can then use this diagnostic information to tailor therapy for excellent patient outcomes. Topera’s 3D Mapping System is the first diagnostic tool designed to identify the patient specific, unique electrophysiologic source that sustains serious heart rhythm disorders.
 
The Topera 3D Mapping System, which consists of the RhythmView Workstation and the FIRMap diagnostic catheter, is designed to improve patient outcomes by enabling electrophysiologists to view a dynamic representation of the electrical activity of the heart, supporting the diagnosis of and treatment planning for a variety of arrhythmias including atrial fibrillation, atrial flutter, atrial tachycardia and ventricular tachycardia. 
 
For more information: www.toperamedical.com

Related Content

Computer Simulations May Treat Most Common Heart Rhythm Disorder

The OPTIMA (Optimal Target Identification via Modelling of Arrhythmogenesis) simulator uses contrast-enhanced MRI scans to create personalized digital replicas of a patient's heart to guide catheter abation for atrial fibrillation. Image courtesy of Patrick M. Boyle and Natalia A. Trayanova.

News | EP Mapping and Imaging Systems | August 19, 2019
Scientists at Johns Hopkins have successfully created personalized digital replicas of the upper chambers of the heart...
Charge Density Mapping Eliminates Repeat Ablation for Atrial Fibrillation at One Year
News | EP Mapping and Imaging Systems | July 15, 2019
Acutus Medical announced the publication of the UNCOVER AF study in Circulation: Arrhythmia and Electrophysiology. The...
Innovative Health Receives FDA Clearance to Reprocess Pentaray Nav Eco High-density Mapping Catheter
News | EP Mapping and Imaging Systems | July 05, 2019
Single-use cardiology medical device reprocessing company Innovative Health, received U.S. Food and Drug Administration...
VIVO 3-D Cardiac Mapping System Cleared by FDA
Technology | EP Mapping and Imaging Systems | July 01, 2019
Catheter Precision Inc. announced that the U.S. Food and Drug Administration (FDA) has cleared its new VIVO (View into...
Algorithm Steers Catheters to Right Spot to Treat Atrial Fibrillation

Using human AFib simulations, the researchers demonstrated that their technique can stop the catheter at the right target and identify the source type with a 95.25 percent success rate. This new algorithm also is effective in scarred tissue, which makes ablation more challenging, and has a 99 percent detection rate regardless of the scar size. Image courtesy of Florida Atlantic University.

News | EP Mapping and Imaging Systems | May 28, 2019
Researchers have developed the first algorithm that can locate patient-specific ablation targets for atrial...
Acutus Medical Announces Rhythm Xience Acquisition, New Partnerships at HRS 2019

Acutus Medical's acquisition of Rhythm Xience brings the Flextra steerable introducer sheath into Acutus Medical's product portfolio.

News | EP Mapping and Imaging Systems | May 17, 2019
At the 40th annual Heart Rhythm Scientific Sessions, May 8-11 in San Francisco, Acutus Medical announced the agreement...
Electromechanical Wave Imaging (EWI) is a new, high-frame rate 3-D rendered ultrasound technique that can noninvasively map the electromechanical activation of heart rhythm. This example shows the ECG tracings compared to the EWI image of the heart.

Electromechanical Wave Imaging (EWI) is a new, high-frame rate 3-D rendered ultrasound technique that can noninvasively map the electromechanical activation of heart rhythm. This example shows the ECG tracings compared to the EWI image of the heart.

Feature | EP Mapping and Imaging Systems | May 15, 2019 | Dave Fornell, Editor
May 15, 2019 — A new study shows electromechanical wave imaging is capable of localizing arrhythmias including atrial
Philips and Medtronic Collaborate on Image-guided Atrial Fibrillation Treatment
News | EP Mapping and Imaging Systems | May 09, 2019
Philips announced a collaboration with Medtronic to further advance treatment of paroxysmal atrial fibrillation (PAF),...
Acutus Medical Receives FDA Clearance for Second-generation AcQMap Platform
Technology | EP Mapping and Imaging Systems | April 26, 2019
Acutus Medical announced U.S. Food and Drug Administration (FDA) clearance of its second-generation AcQMap platform,...
Acutus AcQMap Imaging System Helps Eliminate Arrhythmia With Single Ablation
News | EP Mapping and Imaging Systems | January 28, 2019
Acutus Medical announced 12-month data from the UNCOVER-AF trial investigating the use of the AcQMap advanced cardiac...
Overlay Init